All In MedTech

Device Trial Radar · NCT07323251

Clinical Study on the Effectiveness of Diverse Segments Defocus Optimization in Spectacle Lenses for Slowing Myopia Progression

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

May 19, 2023

Primary completion

Jun 1, 2025

Study completion Nov 16, 2026

Sponsor

Lead sponsor
Beijing Tongren HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 7, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 7 years, up to 15 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Clinical Trial The goal of this clinical trial is to evaluate the effectiveness of two types of Diverse Segments Defocus Optimization (D.S.D.O.) spectacle lenses in slowing myopia progression in children. It will also assess the safety of these lenses. The main questions it aims to answer are: Do D.S.D.O. lenses reduce the progression of myopia as measured by changes in cycloplegic refraction and axial length? What adverse events do participants experience when wearing D.S.D.O. lenses? Researchers will compare two optical designs of D.S.D.O. lenses (Intervention Group1: Design 1; Intervention Group2: Design 2) to determine their relative efficacy in controlling myopia progression. Participants will: Wear assigned D.S.D.O. lenses daily for 12 months (except during sleep or unavoidable situations). Attend clinic visits at baseline, 3, 6, 9, and 12 months for comprehensive eye examinations. Maintain a diary recording daily wear time, visual symptoms, and any adverse events.

Conditions

  • Children With Myopia
  • Treatment
  • Multizone Lens Design for Myopic Defocus
  • Visual Quality
  • Efficacy

Interventions

  • Diverse Segments Defocus Optimization (D.S.D.O.) spectacle lensesDevice

    This clinical trial employs a randomized, parallel-group, superiority design to evaluate two novel optical designs of Diverse Segments Defocus Optimization (D.S.D.O.) myopia management spectacle lenses. A total of 120 myopic Chinese children, aged 7 to 15 years, will be recruited and randomly assigned in a 1:1 ratio to one of two intervention groups. Both groups will receive myopia control spectacles: the PD Group will use lenses with peripheral microlens arrays, and the DCDD Group will use lenses combining identical microlens architecture with light-scattering dot elements. Participants are required to wear the assigned spectacles daily for the entire 12-month study duration, except during sleep or other unavoidable circumstances. These spectacles provide full refractive correction while incorporating defocus and contrast reduction to slow myopia progression.The study includes a baseline visit, a dispensing visit, and follow-up assessments at 3, 6, 9, and 12 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Spherical Equivalent Refraction (SER)Time frame: From enrollment to the end of treatment at 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.